Free flu vaccine and simultaneous vaccination for people over 65...Pfizer Pharmaceutical Co., Ltd. Launches COVID-19 Vaccination Advertising Campaign
Oct 16, 2025
Although awareness of COVID-19 has decreased since the end of the pandemic, COVID-19 is still a respiratory disease with a high disease burden in high-risk groups.
According to a retrospective cohort study conducted in the United States, patients hospitalized with COVID-19 during the 2023-2024 season had an approximately 35% higher risk of death than those hospitalized with seasonal flu. Therefore, COVID-19 vaccination is actively recommended in high-risk groups, including the elderly over 65 years of age.
From the 2025-2026 season, the COVID-19 vaccine will be included in the National Vaccination (NIP) system, and ▲ the elderly aged 65 or older ▲ the immunocompromised ▲ free vaccination will be available to hospitalized and admitted to infectious-vulnerable facilities. The start date of inoculation differs for each target group. ▲The vaccination began on October 15 for those aged 75 or older and those hospitalized and admitted to immunocompromised and infectious facilities, and ▲70-74-year-olds will be inoculated from October 20, and ▲65-69-year-olds will be inoculated from October 22.
In addition, the COVID-19 vaccine requires one dose every year, just like the flu vaccine. This is due to continuous changes in epidemic mutations and a decrease in preventive effects over time after inoculation, and vaccination to respond to the latest mutations is necessary even if inoculated in the past.
In this regard, Pfizer Pharmaceutical Korea will conduct an advertising campaign to encourage the elderly aged 65 or older who are eligible for the COVID-19 Vaccine National Vaccination Project (NIP) during the 2025-2026 season.
Under the concept of 'Pfizer COVID-19 vaccination test', this campaign will deliver accurate information on the subject and duration of COVID-19 National Vaccination (NIP) through a quiz format, ▲ High risk of death compared to the flu of COVID-19 ▲ Free vaccination once a year ▲ Those eligible for free vaccination (aged 65 or older, immunocompromised, hospitalized and admitted to vulnerable facilities) ▲Recommended simultaneous vaccination with the flu vaccine for those aged 65 or older. Through this, it is designed to encourage COVID-19 vaccination and contribute to improving the public health environment in Korea.
One of the national vaccination (NIP) vaccines for COVID-19 in this season, Pfizer Pharmaceutical Korea's new COVID-19 vaccine Cominati® LPate One Freefield Syringe, is an LP.8.1 strain vaccine recommended by the world's major health organizations (WHO, etc.). According to the results of the latest open-label Phase 3 clinical study, titers to LP.8.1 neutralizing antibodies increased more than fourfold, on average, after 14 days of inoculation, in both adults 65 years and older and adults 18–64 years of age with one or more underlying conditions that may progress to severe COVID-19. In particular, this vaccine is a pre-field syringe formulation, and the drug is charged in advance in the syringe.
Song Chan-woo, vice president of the primary care division of Pfizer Pharmaceuticals, said, "We hope that Pfizer's advertising campaign for the COVID-19 vaccination test will serve as an opportunity to promote the risk of COVID-19 and the need for vaccination to the elderly over 65 years of age."" and "Korea Pfizer Pharmaceuticals will continue to cooperate with the government and local governments and contribute to the promotion of public health through various activities such as providing public relations materials to encourage vaccination as well as the stable supply of vaccines to create a COVID-19 prevention environment in Korea.""
According to a retrospective cohort study conducted in the United States, patients hospitalized with COVID-19 during the 2023-2024 season had an approximately 35% higher risk of death than those hospitalized with seasonal flu. Therefore, COVID-19 vaccination is actively recommended in high-risk groups, including the elderly over 65 years of age.
From the 2025-2026 season, the COVID-19 vaccine will be included in the National Vaccination (NIP) system, and ▲ the elderly aged 65 or older ▲ the immunocompromised ▲ free vaccination will be available to hospitalized and admitted to infectious-vulnerable facilities. The start date of inoculation differs for each target group. ▲The vaccination began on October 15 for those aged 75 or older and those hospitalized and admitted to immunocompromised and infectious facilities, and ▲70-74-year-olds will be inoculated from October 20, and ▲65-69-year-olds will be inoculated from October 22.
In addition, the COVID-19 vaccine requires one dose every year, just like the flu vaccine. This is due to continuous changes in epidemic mutations and a decrease in preventive effects over time after inoculation, and vaccination to respond to the latest mutations is necessary even if inoculated in the past.
|
Under the concept of 'Pfizer COVID-19 vaccination test', this campaign will deliver accurate information on the subject and duration of COVID-19 National Vaccination (NIP) through a quiz format, ▲ High risk of death compared to the flu of COVID-19 ▲ Free vaccination once a year ▲ Those eligible for free vaccination (aged 65 or older, immunocompromised, hospitalized and admitted to vulnerable facilities) ▲Recommended simultaneous vaccination with the flu vaccine for those aged 65 or older. Through this, it is designed to encourage COVID-19 vaccination and contribute to improving the public health environment in Korea.
One of the national vaccination (NIP) vaccines for COVID-19 in this season, Pfizer Pharmaceutical Korea's new COVID-19 vaccine Cominati® LPate One Freefield Syringe, is an LP.8.1 strain vaccine recommended by the world's major health organizations (WHO, etc.). According to the results of the latest open-label Phase 3 clinical study, titers to LP.8.1 neutralizing antibodies increased more than fourfold, on average, after 14 days of inoculation, in both adults 65 years and older and adults 18–64 years of age with one or more underlying conditions that may progress to severe COVID-19. In particular, this vaccine is a pre-field syringe formulation, and the drug is charged in advance in the syringe.
Song Chan-woo, vice president of the primary care division of Pfizer Pharmaceuticals, said, "We hope that Pfizer's advertising campaign for the COVID-19 vaccination test will serve as an opportunity to promote the risk of COVID-19 and the need for vaccination to the elderly over 65 years of age."" and "Korea Pfizer Pharmaceuticals will continue to cooperate with the government and local governments and contribute to the promotion of public health through various activities such as providing public relations materials to encourage vaccination as well as the stable supply of vaccines to create a COVID-19 prevention environment in Korea.""
This article was translated by Naver AI translator.
